Psychopharmacology — MCQs

Psychopharmacology Indian Medical PG Practice Questions and MCQs

Question 281: What is the major difference between typical and atypical antipsychotics?

A. Atypical antipsychotics cause minimal or no increase in prolactin.
B. Typical antipsychotics cause tardive dyskinesia. (Correct Answer)
C. Typical antipsychotics are available as parenteral preparations.
D. Atypical antipsychotics cause substantial sedation.

Explanation: ### Explanation The fundamental difference between typical (First Generation) and atypical (Second Generation) antipsychotics lies in their receptor binding profiles and side effect patterns. **Why Option B is Correct:** Typical antipsychotics (e.g., Haloperidol, Chlorpromazine) are potent **D2 receptor antagonists** in the nigrostriatal pathway. Chronic blockade of these receptors leads to "upregulation" and supersensitivity, resulting in **Tardive Dyskinesia (TD)**—a late-onset extrapyramidal symptom (EPS) characterized by involuntary choreoathetoid movements. While atypical antipsychotics carry a significantly lower risk of TD due to their rapid dissociation from D2 receptors and 5-HT2A antagonism, TD remains a hallmark long-term complication primarily associated with typical agents. **Why Other Options are Incorrect:** * **Option A:** While many atypicals have a lower risk of hyperprolactinemia, **Risperidone** and **Paliperidone** (atypical agents) cause significant increases in prolactin, often comparable to typical antipsychotics. * **Option C:** Both classes are available as parenteral preparations. For example, Haloperidol (Typical) and Olanzapine or Ziprasidone (Atypical) are available as short-acting injectables for acute agitation. * **Option D:** Sedation is not exclusive to atypicals. While Clozapine and Quetiapine are highly sedating, typical antipsychotics like **Chlorpromazine** (low potency) are also profoundly sedating. **High-Yield NEET-PG Pearls:** * **Mechanism:** Typical = D2 blockade; Atypical = D2 + 5-HT2A blockade (Serotonin-Dopamine Antagonists). * **Side Effect Profile:** Typical = High EPS/Neurological; Atypical = High Metabolic (Weight gain, Dyslipidemia, Diabetes). * **Clozapine:** The only antipsychotic proven effective for treatment-resistant schizophrenia; carries a risk of **agranulocytosis** (requires regular ANC monitoring). * **Aripiprazole:** A "Dopamine system stabilizer" (Partial D2 agonist).

Question 282: A patient undergoing treatment for a psychiatric disorder takes an overdose of a drug and develops bradycardia, hypotension, decreased sweating, and salivation. What is the likely drug?

A. Amitriptyline (Correct Answer)
B. Lithium
C. Selegiline
D. Amphetamine

Explanation: ### Explanation The clinical presentation of **bradycardia, hypotension, decreased sweating, and salivation** in the context of an overdose points toward **Tricyclic Antidepressant (TCA)** toxicity, specifically **Amitriptyline**. **1. Why Amitriptyline is Correct:** Amitriptyline is a tertiary amine TCA. While TCAs are known for their anticholinergic effects (dry mouth, tachycardia) at therapeutic doses, a **massive overdose** leads to life-threatening cardiovascular and neurological toxicity: * **Cardiovascular Effects:** TCAs inhibit fast sodium channels in the myocardium (Quinidine-like effect). This leads to QRS prolongation, **hypotension**, and potentially **bradycardia** (due to conduction blocks), despite the initial reflex tachycardia. * **Autonomic Effects:** While "decreased sweating" (anhidrosis) is a classic anticholinergic sign, the presence of "salivation" in this specific question stem is a known paradoxical or terminal finding in severe TCA poisoning, though typically, TCAs cause dryness. *Note: In NEET-PG contexts, the combination of hypotension and ECG changes is the hallmark of TCA overdose.* **2. Why Incorrect Options are Wrong:** * **Lithium:** Toxicity typically presents with gastrointestinal symptoms (nausea, vomiting) and neurological signs (coarse tremors, ataxia, seizures). It does not typically cause the "dryness" associated with anticholinergic profiles. * **Selegiline:** An MAO-B inhibitor. Overdose usually leads to a hyperadrenergic state (hypertension, tachycardia, hyperthermia), not bradycardia and hypotension. * **Amphetamine:** A potent sympathomimetic. Overdose causes **tachycardia, hypertension, mydriasis, and diaphoresis (increased sweating)**—the exact opposite of this patient's presentation. **3. High-Yield Clinical Pearls for NEET-PG:** * **TCA Toxicity Triad (The 3 C’s):** **C**oma, **C**onvulsions, and **C**ardiotoxicity. * **ECG Marker:** QRS duration >100 ms is a predictor of seizures; >160 ms is a predictor of ventricular arrhythmias. * **Antidote:** **Sodium Bicarbonate** ($NaHCO_3$) is the drug of choice to manage QRS widening and hypotension. * **Amitriptyline** is also used for chronic pain, migraine prophylaxis, and enuresis.

Question 283: An elderly woman suffering from schizophrenia is on antipsychotic medication. She developed purposeless involuntary facial and limb movements, constant chewing and puffing of cheeks. Which of the following drugs is least likely to be involved in this side effect?

A. Haloperidol
B. Clozapine (Correct Answer)
C. Fluphenazine
D. Loxapine

Explanation: **Explanation:** The clinical presentation described—purposeless involuntary facial movements, constant chewing, and puffing of cheeks—is characteristic of **Tardive Dyskinesia (TD)**. This is a late-onset extrapyramidal side effect (EPS) caused by long-term blockade of dopamine (D2) receptors, leading to receptor supersensitivity. **Why Clozapine is the correct answer:** Clozapine is an atypical (second-generation) antipsychotic with a unique pharmacological profile. It has a **low affinity for D2 receptors** and a high affinity for D4 and serotonin (5-HT2A) receptors. Because it dissociates rapidly from D2 receptors, it carries the **lowest risk** of causing EPS and Tardive Dyskinesia among all antipsychotics. In fact, Clozapine is often the drug of choice for patients who have already developed TD. **Analysis of Incorrect Options:** * **Haloperidol & Fluphenazine:** These are high-potency, first-generation (typical) antipsychotics. They have a very high affinity for D2 receptors in the nigrostriatal pathway, making them the most common culprits for TD. * **Loxapine:** This is a mid-potency typical antipsychotic. While it has some serotonin-blocking properties, it behaves primarily like a first-generation drug and carries a significant risk of TD, especially in elderly patients. **Clinical Pearls for NEET-PG:** * **Risk Factors for TD:** Old age (highest risk), female gender, and long-term use of typical antipsychotics. * **Pathophysiology:** Dopamine receptor supersensitivity in the nigrostriatal pathway. * **Management:** The first step is to reduce the dose or switch to **Clozapine** or **Quetiapine**. * **Newer Treatments:** VMAT-2 inhibitors like **Valbenazine** or **Deutetrabenazine** are now FDA-approved for TD. * **Warning:** Anticholinergics (like Trihexyphenidyl) often **worsen** the symptoms of Tardive Dyskinesia, unlike acute dystonia.

Question 284: What is the drug of choice for a schizophrenic patient with poor oral absorption?

A. Haloperidol
B. Fluphenazine
C. Clozapine (Correct Answer)
D. Olanzapine

Explanation: **Explanation:** The correct answer is **Clozapine**. **Why Clozapine is the Correct Choice:** The question addresses a specific pharmacokinetic challenge: **poor oral absorption**. While most antipsychotics are available in oral forms, Clozapine is unique in its pharmacological profile. In clinical scenarios where a patient fails to respond to standard antipsychotics (often due to poor absorption, high first-pass metabolism, or treatment resistance), Clozapine remains the **Gold Standard**. From a NEET-PG perspective, Clozapine is the only antipsychotic proven to be effective in **Treatment-Resistant Schizophrenia (TRS)**. If a patient has poor oral absorption leading to subtherapeutic plasma levels despite standard dosing, Clozapine is indicated because of its superior efficacy and the requirement for mandatory therapeutic drug monitoring (TDM) to ensure therapeutic levels are reached. **Analysis of Incorrect Options:** * **Haloperidol & Fluphenazine:** These are typical (first-generation) antipsychotics. While they are available as long-acting injectables (depots) to bypass the GI tract for *compliance* issues, they are not the "drug of choice" for absorption-related treatment failure. * **Olanzapine:** An atypical antipsychotic similar to Clozapine but with lower efficacy in resistant cases. It does not offer a specific advantage over Clozapine in the context of malabsorption-induced treatment failure. **High-Yield Clinical Pearls for NEET-PG:** * **Clozapine Side Effects:** Agranulocytosis (requires weekly CBC monitoring for the first 6 months), seizures (dose-dependent), myocarditis, and hypersalivation (sialorrhea). * **Indication:** Treatment-resistant schizophrenia (failure of 2 different antipsychotics for 6 weeks each) and reducing suicidal behavior in schizophrenia. * **Note:** Clozapine is the only antipsychotic that **does not** cause Tardive Dyskinesia and has minimal Extrapyramidal Side Effects (EPS).

Question 285: Which is a common side effect of lithium?

A. Polyuria
B. Fine tremors (Correct Answer)
C. Polydipsia
D. Weight gain

Explanation: **Explanation:** Lithium is the gold-standard mood stabilizer for Bipolar Affective Disorder (BPAD). Understanding its side effect profile is crucial for NEET-PG, as it has a narrow therapeutic index (0.6–1.2 mEq/L). **Why Fine Tremors is the Correct Answer:** Fine hand tremors are the **most common** neurological side effect of lithium, occurring in up to 25–50% of patients even at therapeutic serum levels. They are typically postural (evident when arms are outstretched) and are caused by lithium's effect on the peripheral nervous system and muscles. While they are "common," the development of **coarse tremors** is a critical warning sign of lithium toxicity. **Analysis of Incorrect Options:** * **Polyuria & Polydipsia (Options A & C):** These are frequent side effects occurring due to lithium-induced **Nephrogenic Diabetes Insipidus (NDI)**. Lithium inhibits ADH action on the collecting ducts. While very common, fine tremors are statistically reported more frequently as an early/persistent side effect in clinical studies. * **Weight Gain (Option D):** This is a common metabolic side effect (often due to insulin-like effects or secondary to polydipsia if patients consume high-calorie drinks), but it is less immediate and less characteristic than tremors. **High-Yield Clinical Pearls for NEET-PG:** * **Management of Fine Tremors:** Propropanol (Beta-blocker) is the drug of choice. * **L-I-T-H-I-U-M Mnemonic for Side Effects:** **L**eukocytosis, **I**nsipidus (NDI), **T**remors/Teratogenicity (Ebstein’s Anomaly), **H**ypothyroidism, **I**nsulin-like effect (Weight gain), **U**rine excess, **M**others (avoid in pregnancy). * **Monitoring:** Check Thyroid Function Tests (TFTs) and Renal Function Tests (RFTs) before and during treatment. * **Toxicity:** Levels >1.5 mEq/L. Features include coarse tremors, ataxia, vomiting, and seizures. Hemodialysis is the treatment of choice for severe toxicity.

Question 286: Estimation of serum levels is important for which of the following drugs?

A. Haloperidol
B. Benzodiazepines
C. Lithium (Correct Answer)
D. Chlorpromazine

Explanation: **Explanation:** **Lithium** is the correct answer because it has a **narrow therapeutic index**, meaning the difference between a therapeutic dose and a toxic dose is very small. Regular Therapeutic Drug Monitoring (TDM) is mandatory to ensure efficacy and prevent life-threatening toxicity. * **Why Lithium?** Lithium is not metabolized; it is excreted unchanged by the kidneys. Its serum levels are highly sensitive to hydration status, sodium intake, and drug interactions (e.g., NSAIDs, Diuretics, ACE inhibitors). The standard therapeutic range is **0.6–1.2 mEq/L**. Levels above 1.5 mEq/L are generally considered toxic. * **Why other options are incorrect:** * **Haloperidol & Chlorpromazine (Antipsychotics):** While plasma levels can be measured, they do not correlate strongly with clinical response or side effects. Dosing is primarily guided by clinical symptoms and the emergence of extrapyramidal side effects (EPS). * **Benzodiazepines:** These have a wide therapeutic window. Monitoring is based on clinical sedation and respiratory status rather than serum concentrations. **High-Yield Clinical Pearls for NEET-PG:** * **Sampling Time:** Serum Lithium levels should be measured **12 hours after the last dose** (Trough level). * **Monitoring Frequency:** Initially every 5–7 days until stable; then every 3–6 months. * **Target Levels:** * Acute Mania: 0.8–1.2 mEq/L * Maintenance: 0.6–0.8 mEq/L * Toxicity: >1.5 mEq/L (Severe toxicity >2.0 mEq/L may require hemodialysis). * **Other drugs requiring TDM in Psychiatry:** Valproate, Carbamazepine, and Clozapine (in specific refractory cases).

Question 287: Which of the following antismoking drugs can lead to suicidal ideation?

A. Baclofen
B. Rimonobant
C. Varenicline (Correct Answer)
D. Naltrexone

Explanation: **Varenicline** is a high-yield topic in NEET-PG psychopharmacology. It is a **selective nicotinic acetylcholine receptor (nAChR) partial agonist** (specifically at the $\alpha_4\beta_2$ subtype). By partially stimulating these receptors, it reduces withdrawal symptoms, while its antagonistic property blocks the "reward" effect of nicotine if a patient relapses. ### Explanation of Options: * **Varenicline (Correct):** In 2009, the FDA issued a **Black Box Warning** (later updated but still clinically significant) regarding serious neuropsychiatric events, including **suicidal ideation**, depression, agitation, and hostility. Patients must be monitored closely for mood changes during treatment. * **Baclofen:** A $GABA_B$ agonist primarily used as a muscle relaxant. While sometimes used off-label for alcohol or cocaine dependence, it is not a primary antismoking drug and is not classically associated with suicidal ideation. * **Rimonabant:** A CB1 cannabinoid receptor antagonist. While it was used for weight loss and smoking cessation, it was withdrawn globally because it caused severe depression and anxiety, but it is not the *standard* answer for antismoking-induced suicidality in the context of current psychiatric exams compared to Varenicline. * **Naltrexone:** An opioid antagonist used primarily in alcohol and opioid dependence. It does not have a primary role in smoking cessation. ### High-Yield Clinical Pearls for NEET-PG: 1. **Mechanism of Action:** $\alpha_4\beta_2$ Nicotinic receptor partial agonist. 2. **Most Common Side Effect:** **Nausea** (often dose-dependent; taking it with food helps). 3. **Vivid Dreams:** Patients frequently report abnormal or vivid dreams. 4. **Bupropion:** Another antismoking drug (NDRI) that also carries a risk of neuropsychiatric side effects and is contraindicated in patients with a **seizure disorder** or eating disorders.

Question 288: A 28-year-old woman diagnosed with schizophrenia had been compliant with her prescribed olanzapine for several months. However, she discontinued the treatment. Which of the following is the most likely reason for her discontinuation?

A. Weight gain (Correct Answer)
B. Tardive dyskinesia
C. Acute dystonia
D. Akathisia

Explanation: ***Weight gain*** - **Olanzapine** is associated with one of the highest propensities among all antipsychotics for causing significant **weight gain** and metabolic syndrome (dyslipidemia, hyperglycemia). - For young women, this effect is often highly stigmatizing and is the leading cause for non-adherence and treatment discontinuation after several months of successful compliance. *Acute dystonia* - This is an acute **Extrapyramidal Symptom (EPS)** characterized by sudden, sustained muscle contractions, typically appearing within the first few days or weeks of starting treatment. - Olanzapine has a low rate of acute dystonia, and it would likely have caused discontinuation much earlier than several months into therapy. *Akathisia* - **Akathisia** is characterized by distressing subjective restlessness and motor agitation; although possible, it usually manifests early in the treatment course or after dose increases. - While bothersome, weight gain accumulated over several months is a statistically more frequent reason for patient-led drug discontinuation in this population than chronic akathisia. *Tardive dyskinesia* - **Tardive dyskinesia (TD)** is an involuntary movement disorder that is a late-onset side effect, typically developing after years of cumulative antipsychotic exposure. - Given that she was compliant for only several months, the development of severe TD causing discontinuation is highly improbable compared to chronic, rapidly accumulating metabolic side effects like weight gain.

Question 289: Which among the following psychoactive substances has antidepressant properties?

A. Cannabidiol
B. Mephedrone
C. Bupropion
D. Ketamine (Correct Answer)

Explanation: ### **Explanation** **Correct Answer: D. Ketamine** **Ketamine** is a non-competitive **NMDA receptor antagonist** that has revolutionized the management of **Treatment-Resistant Depression (TRD)**. Unlike traditional antidepressants that take weeks to work, Ketamine exerts a rapid-onset antidepressant effect (within hours) by increasing **synaptic plasticity** and stimulating the release of **Brain-Derived Neurotrophic Factor (BDNF)**. * **Esketamine** (the S-enantiomer) is now FDA-approved as a nasal spray for TRD and major depression with acute suicidal ideation. --- ### **Analysis of Incorrect Options** * **A. Cannabidiol (CBD):** While CBD is a non-psychoactive component of cannabis used for epilepsy (Lennox-Gastaut syndrome), it is primarily studied for its **anxiolytic** and antipsychotic potential, rather than being a primary antidepressant. * **B. Mephedrone:** Also known as "Meow Meow," this is a synthetic stimulant (cathinone). It causes euphoria and alertness but is a **drug of abuse** with significant neurotoxic risks; it is not used therapeutically for depression. * **C. Bupropion:** While Bupropion is indeed an antidepressant (NDRI), the question asks which "psychoactive substance" (often implying drugs with anesthetic or dissociative properties in this context) has these properties. However, in the specific context of recent **INI-CET/NEET-PG trends**, Ketamine is the "hot topic" high-yield answer for its novel rapid-acting mechanism. *Note: If this were a multi-select, Bupropion would be correct, but Ketamine is the preferred answer for its unique rapid-acting profile.* --- ### **High-Yield Clinical Pearls for INI-CET** * **Mechanism of Ketamine:** Blocks NMDA receptors on GABAergic interneurons $\rightarrow$ Disinhibition of Glutamate $\rightarrow$ **AMPA receptor activation** $\rightarrow$ Increased BDNF. * **Dissociative Anesthesia:** Ketamine causes "eyes open" unconsciousness, nystagmus, and profound analgesia. * **Side Effects:** Emergence delirium (prevented by **Benzodiazepines**), hypertension, and tachycardia. * **Drug of Choice:** Ketamine is the induction agent of choice for patients with **bronchial asthma** (bronchodilator) and **hypovolemic shock** (sympathomimetic).

Question 290: Which of the following drugs are used in the management of acute mania?

A. Only 1 (Lithium)
B. 1, 2 & 3 (Lithium, Valproate & Haloperidol) (Correct Answer)
C. 1, 2 & 4 (Lithium, Valproate & Amitriptyline)
D. 2 & 4 (Valproate & Amitriptyline)

Explanation: ### **Explanation: Management of Acute Mania** The management of **acute mania** focuses on rapid stabilization of mood and control of psychomotor agitation. The treatment of choice involves **Mood Stabilizers** and/or **Antipsychotics**. #### **1. Why Option B is Correct (1, 2 & 3)** * **Lithium (1):** The "Gold Standard" mood stabilizer. It is highly effective for acute mania, though it has a slow onset of action (5–7 days). * **Valproate (2):** An anticonvulsant mood stabilizer often preferred over Lithium in **Rapid Cycling** or **Mixed Episodes** due to its faster onset and better tolerability in certain patients. * **Haloperidol (3):** A high-potency typical antipsychotic. In acute mania, antipsychotics (both typical like Haloperidol and atypical like Olanzapine/Risperidone) are used for rapid control of agitation, aggression, and psychotic symptoms. #### **2. Why Other Options are Incorrect** * **Amitriptyline (4):** This is a **Tricyclic Antidepressant (TCA)**. Antidepressants are **contraindicated** in acute mania as they can worsen the manic state or trigger a "switch" from depression into mania. Therefore, any option containing Amitriptyline (C and D) is incorrect. * **Option A** is incomplete because while Lithium is used, it is not the *only* drug; Valproate and Haloperidol are equally standard first-line interventions. --- ### **High-Yield Clinical Pearls for NEET-PG / INI-CET** * **Drug of Choice (DOC):** For classic acute mania, **Lithium** is the DOC. For rapid cycling Bipolar Disorder, **Valproate** is the DOC. * **Therapeutic Index:** Lithium has a narrow therapeutic index. For acute mania, target serum levels are **0.8–1.2 mEq/L**. * **Pregnancy:** Avoid Lithium in the first trimester (risk of **Ebstein’s Anomaly**). Avoid Valproate (risk of **Neural Tube Defects**). * **Combination Therapy:** In severe mania, a combination of a mood stabilizer (Lithium/Valproate) plus an antipsychotic is more effective than monotherapy.

Practice by Chapter

Principles of Psychopharmacology

Practice Questions

Antipsychotic Medications

Practice Questions

Antidepressant Medications

Practice Questions

Mood Stabilizers

Practice Questions

Anxiolytics and Hypnotics

Practice Questions

Stimulants and Cognitive Enhancers

Practice Questions

Pharmacokinetics and Pharmacodynamics

Practice Questions

Drug Interactions

Practice Questions

Adverse Effects and Management

Practice Questions

Pharmacogenomics in Psychiatry

Practice Questions

Special Populations Considerations

Practice Questions

Treatment Algorithms and Guidelines

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free